Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trabectedin mechanism of action and platinum resistance: molecular rationale.

Future oncology (London, England) - 1 Oct 2017

Ray-Coquard Isabelle

Abstract excerpt

Trabectedin presents a complex mode of action affecting key cell biology processes in tumor cells and in the tumor microenvironment. In ovarian cancer patients with a platinum treatment-free interval of 6-12 months treated with trabectedin + pegylated liposomal doxorubicin (PLD) or single-agent PLD, and retreated with platinum after relapse, overall survival was significantly prolonged in the trabectedin + PLD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Biomarkers, Tumor
Share to Dioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoplasms

Share to Platinum

Source

Identifiers

PMID: 29020822
DOI: 10.2217/fon-2017-0318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trabectedin mechanism of action and platinum resistance: molecular rationale.PMID 29020822Read ↗

Biology of ovarian cancer and trabectedin mechanism of action.Semantic proximity Read ↗

A Review of Trabectedin (ET-743): A Unique Mechanism of ActionSemantic proximity Read ↗

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.Semantic proximity Read ↗

Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcriptionSemantic proximity Read ↗

Trabectedin as a chemotherapy option for patients with BRCA deficiencySemantic proximity Read ↗

Systematic analysis of ovarian cancer platinum-resistance mechanisms via text miningSemantic proximity Read ↗

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinSemantic proximity Read ↗

Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma PatientsSemantic proximity Read ↗

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.Semantic proximity Read ↗

Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancerSemantic proximity Read ↗

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialSemantic proximity Read ↗

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.